109 related articles for article (PubMed ID: 18067011)
1. Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen.
McKibbin T; Burzynski J; Greene R; Ochoa-Bayona J; Tsai TW; Callander N; Freytes C
Leuk Lymphoma; 2007 Dec; 48(12):2360-6. PubMed ID: 18067011
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and kinetics of CD34
Takhar H; Mislang AR; Singhal N; Brown MP
Asia Pac J Clin Oncol; 2017 Feb; 13(1):79-86. PubMed ID: 27649817
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
[TBL] [Abstract][Full Text] [Related]
5. Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients.
Meehan KR; Slack R; Gehan E; Herscowitz HB; Areman EM; Ebadi M; Cairo MS; Lippman ME
J Hematother Stem Cell Res; 2002 Apr; 11(2):415-21. PubMed ID: 11983113
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.
Narayanasami U; Kanteti R; Morelli J; Klekar A; Al-Olama A; Keating C; O'Connor C; Berkman E; Erban JK; Sprague KA; Miller KB; Schenkein DP
Blood; 2001 Oct; 98(7):2059-64. PubMed ID: 11567990
[TBL] [Abstract][Full Text] [Related]
7. Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Knudsen LM; Gaarsdal E; Jensen L; Nielsen KJ; Nikolaisen K; Johnsen HE
J Hematother; 1996 Aug; 5(4):399-406. PubMed ID: 8877715
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells.
Klein J; Rey P; Dansey R; Karanes C; Abella E; Cassells L; Hamm C; Flowers M; Couwlier C; Peters W; Baynes R
Bone Marrow Transplant; 1999 Nov; 24(9):959-63. PubMed ID: 10556954
[TBL] [Abstract][Full Text] [Related]
10. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
11. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery.
Faucher C; Le Corroller AG; Chabannon C; Viens P; Stoppa AM; Bouabdallah R; Camerlo J; Vey N; Gravis G; Gastaut JA; Novakovitch G; Mannoni P; Bardou VJ; Moatti JP; Maraninchi D; Blaise D
J Hematother; 1996 Dec; 5(6):663-70. PubMed ID: 9117255
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
13. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
14. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG
Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.
Laport GG; Fleming GF; Waggoner S; Zimmerman TM; Grinblatt DL; Williams SF
Bone Marrow Transplant; 2001 Apr; 27(7):677-81. PubMed ID: 11360105
[TBL] [Abstract][Full Text] [Related]
16. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
Herbert KE; Gambell P; Link EK; Mouminoglu A; Wall DM; Harrison SJ; Ritchie DS; Seymour JF; Prince HM
Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
[TBL] [Abstract][Full Text] [Related]
18. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
19. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]